Maddogrel

Clopidogrel, the active ingredient in Maddogrel, is a P2Y12 receptor antagonist (antiplatelet agent) presented as an oral tablet for systemic use. It is used to reduce the risk of atherothrombotic events in patients who have experienced myocardial infarction, ischemic stroke, or have established peripheral arterial disease.

GNH USA supplies Maddogrel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Maddogrel (clopidogrel) is an antiplatelet medication that targets platelet aggregation pathways.

Myocardial infarction (recent): Reduces the risk of subsequent atherothrombotic events. Ischemic stroke (history): Lowers the chance of recurrent cerebrovascular events. Peripheral arterial disease: Helps prevent limb‑related thrombotic complications.

Common adverse reactions are generally mild, while serious events are rare but require prompt medical attention.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal discomfort - Rash - Bruising

Serious or Rare Side Effects: - Severe bleeding (including intracranial hemorrhage) - Thrombotic thrombocytopenic purpura - Neutropenia or agranulocytosis - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Elevated liver enzymes - Unexplained sudden death (very rare)

Before prescribing Maddogrel, clinicians should evaluate patient‑specific factors and monitor therapy regularly.

Bleeding risk assessment: Evaluate history of gastrointestinal bleeding or hemorrhagic disorders. Concomitant anticoagulants: Review use of warfarin, heparin or direct oral anticoagulants. Renal function: Adjust monitoring in patients with severe renal impairment. Liver function: Monitor hepatic enzymes in patients with liver disease. Pregnancy and lactation: Consider risks and benefits; use only if clearly indicated. Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Clopidogrel may interact with several medicines, altering its antiplatelet effect or increasing bleeding risk.

Major Interactions (Avoid): - Oral anticoagulants (e.g., warfarin, dabigatran): Combined use markedly increases bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs, aspirin): Additive effect on bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: Enhance platelet dysfunction and bleeding.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors (omeprazole, esomeprazole): May reduce clopidogrel activation. - CYP2C19 inhibitors (fluoxetine, fluconazole): Potentially decrease antiplatelet activity. - Statins metabolized by CYP3A4 (atorvastatin, simvastatin): May increase plasma levels of clopidogrel metabolites.